Vertex Pharmaceuticals Stock Jumps as Non-Opioid Painkiller Gets FDA Approval
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
FDA approves first new non-opioid pain pill in 20 years—how it works
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
The Motley Fool10d
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Why This Beaten-Down Growth Stock Is a No-Brainer Buy on ...
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan. 30, 2025. Journavx is a first-in-class non-opioid painkiller that acts on sodium channels in the ...